State Street SPDR S&P Biotech ETF
XBI
XBI
621 hedge funds and large institutions have $10.7B invested in State Street SPDR S&P Biotech ETF in 2025 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 159 increasing their positions, 274 reducing their positions, and 103 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
35% less call options, than puts
Call options by funds: $1.47B | Put options by funds: $2.24B
42% less repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 274
47% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 103
Holders
621
Holding in Top 10
15
Calls
$1.47B
Puts
$2.24B
Top Buyers
| 1 | +$399M | |
| 2 | +$291M | |
| 3 | +$182M | |
| 4 |
BC
Broadwater Capital
Boston,
Massachusetts
|
+$80.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$59.4M |
Top Sellers
| 1 | -$248M | |
| 2 | -$246M | |
| 3 | -$199M | |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$48.7M |
| 5 |
Squarepoint
New York
|
-$38.6M |